HCA Healthcare (NYSE:HCA) COO Jon Foster Sells 10,000 Shares of Company Stock

HCA Healthcare, Inc. (NYSE:HCA) COO Jon Foster sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $514.07, for a total value of $5,140,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

HCA Healthcare Stock Down 2.6%

Shares of NYSE:HCA opened at $494.44 on Friday. HCA Healthcare, Inc. has a fifty-two week low of $353.99 and a fifty-two week high of $556.52. The company has a market cap of $103.28 billion, a PE ratio of 16.38, a P/E/G ratio of 1.56 and a beta of 1.11. The company’s 50-day moving average price is $443.66 and its 200 day moving average price is $445.25.

HCA Healthcare (NYSE:HCA) last released its earnings results on Tuesday, October 27th. The company reported $7.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.65 by $0.57. HCA Healthcare had a negative return on equity of 198.52% and a net margin of 8.61%. The firm had revenue of $19.85 billion during the quarter, compared to analysts’ expectations of $19.33 billion. During the same quarter in the prior year, the company earned $6.96 EPS. The company’s revenue was up 3.6% on a year-over-year basis. As a group, equities analysts anticipate that HCA Healthcare, Inc. will post 30.15 EPS for the current year.

HCA Healthcare Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 29th. Shareholders of record on Tuesday, December 15th will be given a $0.78 dividend. This represents a $3.12 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, December 15th. HCA Healthcare’s dividend payout ratio is 10.34%.

Institutional Investors Weigh In On HCA Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MidFirst Bank acquired a new stake in HCA Healthcare during the 2nd quarter worth approximately $28,000. Clearstead Trust LLC acquired a new stake in HCA Healthcare in the second quarter valued at approximately $29,000. Latitude Advisors LLC purchased a new stake in shares of HCA Healthcare during the third quarter worth $32,000. Cedar Mountain Advisors LLC purchased a new position in shares of HCA Healthcare in the 1st quarter valued at about $33,000. Finally, Delos Wealth Advisors LLC purchased a new position in HCA Healthcare in the second quarter valued at about $35,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

Key Stories Impacting HCA Healthcare

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: Investors have welcomed expectations that a Democratic-controlled Congress could provide a policy tailwind for hospitals. However, the anticipated relief is not yet enacted and still depends on legislative and funding steps. HCA Healthcare Gains Policy Tailwind
• Positive Sentiment: HCA is expanding AI tools, with its nurse handoff technology heading to 100 hospitals and ambient AI expected to reach 10,000 physicians by year-end. These deployments could support workflow efficiency. AI nurse handoff tool
• Positive Sentiment: Analyst and technical coverage is supportive: Truist reaffirmed its Buy rating, while Zacks highlighted earnings growth, price strength and a bullish moving-average signal. Truist reaffirms Buy rating Zacks stock outlook
• Neutral Sentiment: HCA completed a $6.5 billion senior notes offering. The report confirms the financing but gives limited detail on its use or effect on borrowing costs. Senior notes offering
• Neutral Sentiment: HCA’s AI chief emphasized that delaying a rollout can be appropriate, suggesting a measured approach that may limit near-term adoption while managing implementation risks. HCA AI rollout strategy
• Negative Sentiment: One report flagged potential payer pressure in HCA’s 2027 outlook, a concern for future hospital reimbursement and margins. Payer pressure outlook
• Negative Sentiment: Pomerantz LLP said it is investigating investor claims involving HCA. The announcement provides no findings, but the inquiry may create a legal overhang. Investor investigation announcement

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of HCA Healthcare in a research report on Friday, October 2nd. Robert W. Baird raised their price target on shares of HCA Healthcare from $393.00 to $409.00 and gave the company a “neutral” rating in a research report on Wednesday, October 28th. Jefferies Financial Group set a $450.00 price objective on HCA Healthcare in a research note on Tuesday, July 14th. Barclays boosted their price target on shares of HCA Healthcare from $387.00 to $401.00 and gave the stock an “equal weight” rating in a report on Thursday, October 29th. Finally, BMO Capital Markets began coverage on shares of HCA Healthcare in a research note on Tuesday, September 22nd. They set an “outperform” rating and a $495.00 price objective on the stock. Sixteen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, HCA Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $480.13.

About HCA Healthcare

HCA Healthcare is a healthcare services company that operates hospitals and other care facilities. Its services include inpatient and outpatient care, emergency treatment, surgery, diagnostic services and specialized care across areas such as cancer and cardiovascular medicine.

The company serves patients in the United States and the United Kingdom through its network of hospitals and outpatient facilities, including surgery centers, urgent care clinics and physician practices.

Founded in 1968, HCA Healthcare is headquartered in Nashville, Tennessee.